



NEW YORK CITY DEPARTMENT OF
HEALTH AND MENTAL HYGIENE

Ashwin Vasan, MD, PhD

Commissioner

January 16, 2024

Dear Vaccines for Children (VFC) Provider:

This is an update on nirsevimab (Beyfortus™--manufactured by Sanofi and AstraZeneca), the monoclonal antibody product used to prevent respiratory syncytial virus (RSV) infections in infants and young children.

Infants and young children recommended to receive nirsevimab should be immunized as soon as possible. [RSV infections remain elevated](#) in New York City. Healthcare providers should **not** reserve nirsevimab for later in the season, when RSV circulation and risk of exposure to RSV may be lower compared with now.

Healthcare providers should administer a single dose of nirsevimab to all infants aged less than 8 months whose birthing parent did not receive RSV vaccine during pregnancy, as well as to all children ages 8 through 19 months at increased risk.

These updates are related to an increase in nirsevimab supply and the [manufacturers' plan to release an additional 230,000 doses in January](#). The [Centers for Disease Control and Prevention \(CDC\) now advises](#) healthcare providers to follow the [original Advisory Committee on Immunization Practices \(ACIP\) recommendations](#) on the use of nirsevimab in infants and young children.

We continue to receive periodic allocations of nirsevimab from CDC for VFC-eligible children. Please email nycimmunize@health.nyc.gov when you need additional doses. Include your VFC pin and the requested number of doses for each presentation (100mg and/or 50mg).

Available supply may continue to vary by healthcare facility. For providers who continue to have limited supply, nirsevimab should be prioritized to protect infants at the highest risk for severe RSV disease, using the following principles: first, by high-risk conditions, and then by age, prioritizing the youngest infants first.

For questions on nirsevimab, or any other immunization issue, call 347.396.2400 or email nycimmunize@health.nyc.gov.

Thank you for your efforts to protect New York City children from RSV.

Sincerely,

A handwritten signature in black ink that reads 'Bindy Crouch'.

Bindy Crouch, MD, MPH
Assistant Commissioner
Bureau of Immunization